Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A2aR Antagonists: Next Generation Checkpoint Blockade For Cancer Immunotherapy

Robert D Leone, Ying-Chun Lo, J. Powell
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The last several years have witnessed exciting progress in the development of immunotherapy for the treatment of cancer. This has been due in great part to the development of so-called checkpoint blockade. That is, antibodies that block inhibitory receptors such as CTLA-4 and PD-1 and thus unleash antigen-specific immune responses against tumors. It is clear that tumors evade the immune response by usurping pathways that play a role in negatively regulating normal immune responses. In this regard, adenosine in the immune microenvironment leading to the activation of the A2a receptor has been shown to represent one such negative feedback loop. Indeed, the tumor microenvironment has relatively high concentrations of adenosine. To this end, blocking A2a receptor activation has the potential to markedly enhance anti-tumor immunity in mouse models. This review will present data demonstrating the ability of A2a receptor blockade to enhance tumor vaccines, checkpoint blockade and adoptive T cell therapy. Also, as several recent studies have demonstrated that under certain conditions A2a receptor blockade can enhance tumor progression, we will also explore the complexities of adenosine signaling in the immune response. Despite important nuances to the A2a receptor pathway that require further elucidation, studies to date strongly support the development of A2a receptor antagonists (some of which have already been tested in phase III clinical trials for Parkinson Disease) as novel modalities in the immunotherapy armamentarium.
This paper references
10.1016/S0006-2952(00)00414-7
Apparent involvement of the A(2A) subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils.
S. S. Visser (2000)
10.1152/AJPHEART.1987.252.5.H886
Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia.
H. van Belle (1987)
10.1038/nrd2638
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
G. Haskó (2008)
10.1073/pnas.0605251103
A2A adenosine receptor protects tumors from antitumor T cells
A. Ohta (2006)
10.1146/ANNUREV.PA.35.040195.003053
Adenosine receptor subtypes: characterization and therapeutic regulation.
M. E. Olah (1995)
10.1200/jco.2014.32.18_suppl.lba9003
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
H. Kluger (2014)
10.1016/J.YONC.2012.07.009
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
10.1111/j.1600-065X.2010.00923.x
The PD‐1 pathway in tolerance and autoimmunity
Loise M. Francisco (2010)
10.1182/BLOOD-2007-03-081646
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.
P. Zarek (2008)
10.1016/s0021-9258(19)40234-2
Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP.
A. Filippini (1990)
10.1111/j.1600-065X.1998.tb01574.x
Ecto‐enzyme and signaling functions of lymphocyte CD 7 3
R. Resta (1998)
10.1126/science.270.5238.985
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
10.1016/1074-7613(95)90125-6
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
- in fi ltrating CD 8 + T lymphocytes are oligoclonal and PD - 1 +
W Zou (2009)
10.1007/s13277-015-3212-x
The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma
B. Zhang (2015)
10.1073/pnas.0908801107
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
J. Stagg (2010)
10.4049/jimmunol.178.7.4240
Activation of Adenosine 2A Receptors Attenuates Allograft Rejection and Alloantigen Recognition1
Charles P. Sevigny (2007)
Dendritic cells tolerizedwith adenosine A(2)AR agonist attenuate acute kidney injury
L Li (2012)
10.1517/14728222.2014.955794
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
B. Henick (2014)
10.1007/s11302-012-9350-3
A2B adenosine receptor blockade inhibits growth of prostate cancer cells
Qiang Wei (2012)
10.1016/S1074-7613(01)00259-X
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.
J. Egen (2002)
10.1073/pnas.1222251110
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
S. Loi (2013)
10.1158/0008-5472.CAN-14-0957
Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.
D. Mittal (2014)
10.1155/2014/460654
The Roles of CD73 in Cancer
Z. Gao (2014)
10.1158/0008-5472.CAN-12-0420
CD73-deficient mice are resistant to carcinogenesis.
J. Stagg (2012)
10.1158/2159-8290.CD-14-0341
Targeting cancer-derived adenosine: new therapeutic approaches.
A. Young (2014)
10.1155/2012/485156
CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth
B. Allard (2012)
10.1111/j.1600-065X.1995.tb00680.x
Role of Extracellular ATP and P1 and P2 Classes of Purinergic Receptors in T‐cell Development and Cytotoxic T Lymphocyte Effector Functions
S. Apasov (1995)
10.1002/(SICI)1098-2299(199611/12)39:3/4<243::AID-DDR3>3.0.CO;2-R
Molecular characterization of recombinant human adenosine receptors
A. Robeva (1996)
10.1101/cshperspect.a006908
Historical overview of immunological tolerance.
R. Schwartz (2012)
10.1172/JCI94890
Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.
A. Grenz (2017)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1152/AJPCELL.1993.265.3.C577
Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides.
G. Dubyak (1993)
Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.
R. Iannone (2014)
10.1152/JAPPL.1994.76.1.5
Adenosine, an endogenous anti-inflammatory agent.
B. Cronstein (1994)
10.1053/J.GASTRO.2005.05.032
Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease.
M. Odashima (2005)
10.1038/bjc.2014.348
Immune modulation for cancer therapy
J. Naidoo (2014)
10.1165/rcmb.2008-0168OC
The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion.
K. Scheibner (2009)
10.1146/annurev.immunol.26.021607.090331
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
10.1200/JCO.2012.48.3685
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
P. Armand (2013)
Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor.
S. Apasov (1997)
10.1084/jem.20062512
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
S. Deaglio (2007)
10.1007/s00262-011-1155-7
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
A. Waickman (2011)
10.1038/nrd3626
The secret ally: immunostimulation by anticancer drugs
L. Galluzzi (2012)
10.1038/35105024
T-cell regulation by CD28 and CTLA-4
M. Alegre (2001)
10.11501/3169195
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Y. Yang (1997)
10.1111/j.1600-065X.2009.00767.x
PD‐1 signaling in primary T cells
J. Riley (2009)
10.4049/jimmunol.169.7.3581
B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis1
M. M. Mazanet (2002)
10.1038/nature13085
Nucleotide signalling during inflammation
M. Idzko (2014)
10.1084/JEM.174.3.561
CTLA-4 is a second receptor for the B cell activation antigen B7
P. Linsley (1991)
10.1158/0008-5472.CAN-06-4249
Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.
T. Raskovalova (2007)
10.4161/auto.27643
Autophagy in non-small cell lung carcinogenesis
S. Rao (2014)
10.1146/annurev-immunol-032712-100008
Immunogenic cell death in cancer therapy.
G. Kroemer (2013)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002;16:23–35
JG Egen (2002)
10.1016/j.bbamem.2010.09.020
Adenosine receptors and cancer.
S. Gessi (2011)
10.1086/386311
A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis.
G. Sullivan (2004)
10.1128/MCB.25.21.9543-9553.2005
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
R. Parry (2005)
10.1002/j.1460-2075.1992.tb05481.x
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y. Ishida (1992)
10.1158/0008-5472.CAN-13-3583
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Caglar Cekic (2014)
10.1053/j.gastro.2008.10.037
Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia.
Julio C. Morote-García (2009)
phoproliferative disorders with early lethality in mice de fi cient in Ctla - 4
P Waterhouse (1995)
10.1038/cdd.2013.75
Molecular mechanisms of ATP secretion during immunogenic cell death
I. Martins (2014)
The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.
J. Blay (1997)
10.1158/0008-5472.CAN-10-4246
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
J. Stagg (2011)
10.1097/CJI.0b013e318156e47e
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
10.1016/S1470-2045(13)70551-5
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
J. Westin (2014)
10.1158/1078-0432.CCR-13-0545
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
B. Allard (2013)
10.1182/blood-2008-02-136325
Adenosine receptors in regulation of dendritic cell differentiation and function.
S. Novitskiy (2008)
10.4049/jimmunol.177.5.2765
Cutting Edge: Critical Role for A2A Adenosine Receptors in the T Cell-Mediated Regulation of Colitis1
M. Naganuma (2006)
10.1158/2326-6066.CIR-14-0075
Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
M. Sitkovsky (2014)
10.1016/j.cellimm.2012.07.001
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.
H. J. Park (2012)
10.1182/BLOOD-2003-06-1959
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells.
Max Schnurr (2004)
10.1007/s40263-014-0161-7
Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
A. Pinna (2014)
10.4049/jimmunol.1101845
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
Caglar Cekic (2012)
10.1056/NEJMra1205750
Purinergic signaling during inflammation.
H. Eltzschig (2012)
10.1172/JCI45559
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
L. Wang (2011)
10.1165/RCMB.2004-0129OC
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells.
J. Kim (2005)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Computational and Structural Biotechnology Journal
R D Leone (2015)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.2217/imt.13.154
Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis.
L. Qin (2014)
10.1038/nm863
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
T. Curiel (2003)
10.1002/pros.21020
Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+
K. Sfanos (2009)
10.1080/08916930701464939
Adenosine and anergy
P. Zarek (2007)
10.1172/JCI63170
Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury.
L. Li (2012)
10.1038/nm730
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
10.1158/0008-5472.CAN-13-3581
Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.
Caglar Cekic (2014)
Human
KS Sfanos
10.1002/eji.201041292
Altered purinergic signaling in CD73‐deficient mice inhibits tumor progression
G. Yegutkin (2011)
10.1189/jlb.3A0513-302RR
Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors
E. Sciaraffia (2014)
10.1385/IR:36:1:91
Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-Activated NK cells
T. Raskovalova (2006)
10.1084/jem.20130249
Extracellular adenosine regulates naive T cell development and peripheral maintenance
Caglar Cekic (2013)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1016/S0165-6147(99)01293-6
Two novel families of ectonucleotidases: molecular structures, catalytic properties and a search for function.
H. Zimmermann (1999)
10.1158/2326-6066.CIR-14-0211
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
P. Beavis (2015)
10.1186/ar1914
Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis
M. Montesinos (2006)
10.1038/nri2326
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
10.1073/pnas.1308209110
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis (2013)
10.1002/eji.200939897
The A2aR adenosine receptor controls cytokine production in iNKT cells
Michael Nowak (2010)
10.1038/nm0902-1039c
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Chemotherapy with immunogenic cell death inducers
E. Vacchelli (2012)
10.1038/414916a
Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage
A. Ohta (2001)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1126/science.1160062
CTLA-4 Control over Foxp3+ Regulatory T Cell Function
K. Wing (2008)
10.1053/j.seminoncol.2010.09.010
Clinical development of the anti-CTLA-4 antibody tremelimumab.
A. Ribas (2010)



This paper is referenced by
10.1186/s12920-016-0212-7
A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer
Hsiao-Rong Chen (2016)
10.1002/med.21432
Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging
A. Waarde (2018)
10.1021/acs.jmedchem.6b00653
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
Elena Segala (2016)
10.1016/j.bmc.2016.04.048
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.
L. Squarcialupi (2016)
10.1007/978-3-030-21477-7_4
Novel Methods to Overcome Acquired Resistance to Immunotherapy
Xianda Zhao (2019)
10.1038/ni.3466
Immunometabolism of regulatory T cells
Ryan H Newton (2016)
10.1080/2162402X.2016.1208875
Targeting CD73 in the tumor microenvironment with MEDI9447
C. Hay (2016)
10.1172/JCI89455
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
P. Beavis (2017)
10.1186/s13045-018-0582-8
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo (2018)
10.3389/fimmu.2017.00688
Applying Precision Medicine and Immunotherapy Advances from Oncology to Host-Directed Therapies for Infectious Diseases
R. Mahon (2017)
10.1155/2018/1982423
Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
M. Witkowska (2018)
10.17077/etd.nfh7-isfe
Ebola virus: entry, pathogenesis and identification of host antiviral activities
Bethany A. Rhein (2015)
10.1016/j.chembiol.2017.08.019
Small-Molecule Targets in Immuno-Oncology.
D. Dhanak (2017)
10.3390/pharmaceutics10040260
Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
Seok-Ho Shin (2018)
10.1016/j.clcc.2018.06.004
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non‐MSI‐H Metastatic Colorectal Cancer
J. Lee (2018)
10.1158/2326-6066.CIR-18-0056
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
S. Willingham (2018)
10.1016/B978-0-08-100625-2.00011-8
Drug discovery: Standing on the shoulders of giants
S. Miller (2017)
10.1097/PPO.0000000000000241
Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy
I. Giuroiu (2017)
10.1016/j.thromres.2018.12.014
Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor.
S. Raposeiras-Roubín (2019)
10.1016/j.cell.2017.01.042
Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity
A. Glukhova (2017)
10.3389/fimmu.2019.00162
Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8+T-Cells
C. Sorrentino (2019)
10.1080/17460441.2018.1534825
Targeting adenosine A2A receptor antagonism for treatment of cancer
M. Congreve (2018)
10.21037/sci.2017.03.04
Immune checkpoint blockade for hematologic malignancies: a review.
Matthew J Pianko (2017)
Association d'un modulateur de points de contrôle immunologiques et d'un complexe comprenant un peptide de pénétration cellulaire, un cargo et un agoniste des peptides tlr pour une utilisation en médecine
Madiha Derouazi (2017)
10.1080/2162402X.2019.1599635
A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity
Nadine Nelson (2019)
10.18632/oncotarget.14434
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
Y. Inoue (2017)
10.1002/1873-3468.14017
G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
Nadia Arang (2020)
10.1136/jitc-2019-000379
T lymphocyte-targeted immune checkpoint modulation in glioma
W. Kelly (2020)
10.1016/j.arr.2017.07.002
Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules
Joanne K Gardner (2017)
10.22038/IJBMS.2016.7820
Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)
V. Homayouni (2016)
10.1186/s40425-019-0758-y
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Wendy Mao (2019)
10.1007/978-3-030-55031-8
Notch Signaling in Embryology and Cancer: Notch Signaling in Cancer
J. Reichrath (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar